SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
392.00    2.00 (0.51%)
Bid:
385.00
Ask:
399.00
Spread: 14.00 (3.636%)
Market Cap: £188.15m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

Products approved by Australia's TGA

27 Feb 2017 07:00

RNS Number : 8584X
Tristel PLC
27 February 2017
 

 

Tristel plc

("Tristel" or the "Company")

 

Fuse for Stella products approved by Australia's Therapeutic Goods Association

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention, contamination control and hygiene products, announces that its Fuse disinfectant used in its Stella decontamination tray has been approved as a high-level disinfectant by Australia's Therapeutic Goods Association ("TGA").

 

Stella and Fuse are specifically designed for the decontamination of small single-channelled instruments, with a particular focus on urology. Flexible cystoscopes are used by urologists for urethral, bladder and kidney examinations and Stella is targeted at this instrument. However, it can also be used to decontaminate bronchoscopes used in respiratory medicine, laryngoscopes used in anaesthesia, manometry catheters used in GI physiology, transoesophageal echo probes used in cardiology, and nasendoscopes used in hospital ear, nose and throat clinics.

 

First introduced to the global hospital market in 2011, 600 Stella systems have been sold worldwide and Fuse and Stella registered £1 million sales for the Company during its last financial year.

 

Stella is a plastic tray sculptured to accommodate cystoscopes whilst occupying minimal work-top space. It is battery-powered, requiring no connection to hospital services and is service / maintenance free. It is the world's only plug and play decontamination concept. Stella achieves all the outcomes of automated endoscope washers at a fraction of their cost and with none of their complexity and operational unreliability. Fuse delivers Tristel's high-level disinfectant into the Stella tray.

 

Tristel has had a presence in the Australian hospital market since 2011 when it received its first approval from the TGA for its Wipes System. From 2011 to 2016 Tristel was represented in the country by a distributor, and in August Tristel purchased the distributor's business and established a direct presence in the Australian hospital market via its wholly-owned subsidiary, Tristel Pty Limited.

 

Paul Swinney, CEO of Tristel plc, comments: "Every regulatory approval gained is a key milestone for Tristel, but this one is particularly exciting. Australia has been a very successful and profitable market for us, and the acquisition of our distributor's business in August 2016 has surpassed expectations. Since the acquisition, we have gained approvals for our Fuse for Surfaces, Jet for Surfaces and Rinse Assure products, and now we have Fuse for Stella to add to the portfolio our team can sell. Australia is a hospital market that has a real need for the Stella decontamination concept, with so many of the country's thousand or so public and private hospitals in remote locations."

 

For further information please contact:

Tristel plc

www.tristel.com

Paul Swinney, Chief Executive 

Tel: 01638 721 500

Liz Dixon, Finance Director

 

 

 

finnCap

 

Geoff Nash / Giles Rolls, Corporate Finance

Tel: 020 7220 0500

Alice Lane, Corporate Broking

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 or tristel@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRADMGZZNVRGNZM
Date   Source Headline
10th Jun 20267:00 amRNSExercise of Share Options & Total Voting Rights
13th May 202610:10 amRNSExercise of Share Options and Total Voting Rights
5th May 20267:00 amRNSExercise of Share Options and Total Voting Rights
20th Apr 20262:28 pmRNSHolding(s) in Company
20th Apr 20268:20 amRNSHolding(s) in Company
23rd Mar 20267:00 amRNSDirector/PDMR Shareholding
18th Mar 20267:00 amRNS-RConference attendance at ShareSoc Leeds
17th Mar 20265:13 pmRNSHolding(s) in Company
3rd Mar 20264:04 pmRNSPCA Dealing
2nd Mar 20267:00 amRNSHalf-year Financial Report
12th Feb 20267:00 amRNSExercise of Share Options and Total Voting Rights
6th Feb 202611:56 amRNSExercise of Share Options and Total Voting Rights
6th Feb 20267:00 amRNSNotice of Results
22nd Jan 20267:00 amRNSPositive H1 Trading Update & Directorate Change
8th Jan 20263:10 pmRNSExercise of Share Options and Total Voting Rights
12th Dec 202510:37 amRNSDirector/PDMR Shareholding
12th Dec 20259:19 amRNSExercise of Share Options and Total Voting Rights
11th Dec 202511:54 amRNSResult of AGM
11th Dec 20257:00 amRNSAGM Statement
24th Nov 202512:28 pmRNSDirector Option Grant
24th Nov 20257:00 amRNSUpdated US guidelines for high level disinfection
18th Nov 20257:00 amRNSNotice of AGM & Posting of Annual Report &Accounts
12th Nov 202511:33 amRNSHolding(s) in Company
31st Oct 20254:11 pmRNSHolding(s) in Company
31st Oct 20252:12 pmRNSHolding(s) in Company
22nd Oct 20254:56 pmRNSHolding(s) in Company
16th Oct 20254:00 pmRNSExercise of Share Options and Total Voting Rights
13th Oct 202512:00 pmRNSExercise of Share Options and Total Voting Rights
13th Oct 20257:00 amRNSFinal Results
9th Oct 202510:06 amRNSExercise of Share Options and Total Voting Rights
25th Sep 20257:00 amRNSVISICLEAN Product Launch
16th Sep 20257:00 amRNSNotice of Preliminary Results
11th Sep 20257:00 amRNSExercise of Share Options and Total Voting Rights
1st Sep 20257:00 amRNSConfirmation of CFO Appointment
21st Aug 20253:56 pmRNSHolding(s) in Company
18th Aug 202512:15 pmRNSExercise of Share Options and Total Voting Rights
6th Aug 20254:05 pmRNS-RCapital Markets Day video update
29th Jul 20257:00 amRNSTrading update
24th Jul 20257:00 amRNSConfirmation of Investor presentations
17th Jul 20257:00 amRNSAppointment of Chief Financial Officer
4th Jul 20251:02 pmRNSHolding(s) in Company
26th Jun 20257:00 amRNS-RAPIC25 Annual Conference attendance
2nd Jun 20257:00 amRNSInvestor Presentations & Notice of Trading Update
30th May 20257:00 amRNSHolding(s) in Company
28th May 20257:00 amRNS-RConference attendance at Mello2025 Investor event
16th May 20257:00 amRNSExercise of Share Options and Total Voting Rights
15th May 20257:00 amRNSCFO succession planning
12th May 20257:00 amRNSFDA clearance for Tristel OPH
10th Apr 20257:00 amRNSAdditional info. submitted to FDA for Tristel OPH
9th Apr 20257:00 amRNSPublication of Poster by Mayo Clinic & US update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.